Compare · ORKA vs QDEL
ORKA vs QDEL
Side-by-side comparison of Oruka Therapeutics Inc. (ORKA) and QuidelOrtho Corporation (QDEL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ORKA and QDEL operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- ORKA is the larger of the two at $3.10B, about 3.6x QDEL ($860.7M).
- Over the past year, ORKA is up 482.9% and QDEL is down 56.6% - ORKA leads by 539.5 points.
- ORKA has been more active in the news (15 items in the past 4 weeks vs 13 for QDEL).
- QDEL has more recent analyst coverage (18 ratings vs 11 for ORKA).
- Company
- Oruka Therapeutics Inc.
- QuidelOrtho Corporation
- Price
- $62.54-8.87%
- $12.63+2.81%
- Market cap
- $3.10B
- $860.7M
- 1M return
- +23.87%
- -23.89%
- 1Y return
- +482.85%
- -56.61%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 15
- 13
- Recent ratings
- 11
- 18
QuidelOrtho Corporation
Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology worldwide. It offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus, a POC products to detect infectious and inflammatory diseases and conditions of the eye. The company also provides Triage MeterPro, a portable testing platform that enables physicians to promote enhanced health outcomes, as well as the detection of certain drugs of abuse; Triage BNP test for use on Beckman Coulter lab analyzers; and Triage TOX drug screen, which provides results for the determination of the presence of drug and/or the major metabolites in urine. In addition, it offers traditional cell lines, specimen collection devices, media, and controls for use in laboratories that culture and test for various human viruses, including respiratory and herpes family viruses; and cell-based products comprising tubes, shell vials, and multi-well plates. Further, the company provides biomarkers, which include clinical and research products for the assessment of osteoporosis and the evaluation of bone resorption/formation; and enzyme linked immunosorbent assays and reagents for the detection of activation products. Additionally, it offers Lyra molecular real-time polymerase chain reaction assays; Solana, an amplification and detection system; and Virena, a wireless cellular data management and surveillance system The company markets its products through distributors and direct sales force for use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail and urgent care clinics, pharmacies, and wellness screening centers. Quidel Corporation was incorporated in 1979 and is headquartered in San Diego, California.
Latest ORKA
- Chief Operating Officer Sandler Laura Lee exercised 5,000 shares at a strike of $7.80 and sold $319,384 worth of shares (5,000 units at $63.88) as part of a pre-agreed trading plan (SEC Form 4)
- Oruka Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
- SEC Form 424B5 filed by Oruka Therapeutics Inc.
- Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering
- SEC Form 424B5 filed by Oruka Therapeutics Inc.
- SEC Form 424B5 filed by Oruka Therapeutics Inc.
- Oruka Therapeutics Announces Proposed $500 Million Underwritten Public Offering
- Oruka Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque Psoriasis
- Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Trial on April 27, 2026
Latest QDEL
- EVP Global Port. Mgmt & Mkting Hanson Bryan Michael was granted 1,459 shares and covered exercise/tax liability with 528 shares, increasing direct ownership by 30% to 4,070 units (SEC Form 4) (withholding obligation)
- Chief Operations Officer Mclellan Philip D. was granted 1,946 shares and covered exercise/tax liability with 699 shares, increasing direct ownership by 6% to 22,497 units (SEC Form 4) (tax liability)
- SEC Form DEFA14A filed by QuidelOrtho Corporation
- SEC Form DEF 14A filed by QuidelOrtho Corporation
- Chief Operations Officer Mclellan Philip D. was granted 3,238 shares and covered exercise/tax liability with 1,162 shares, increasing direct ownership by 11% to 21,250 units (SEC Form 4) (for tax liability)
- EVP Global Port. Mgmt & Mkting Hanson Bryan Michael was granted 3,508 shares and covered exercise/tax liability with 1,269 shares, increasing direct ownership by 249% to 3,139 units (SEC Form 4) to cover taxes
- Understanding and Addressing Syphilis Trends - and What's Being Missed
- SEC Form 4 filed by Sisitsky Nathaniel
- TTP Group Announces the Sale of LEX Diagnostics
- QuidelOrtho Corporation Completes Acquisition of LEX Diagnostics